These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8996568)

  • 1. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
    Lemez P; Maresová J
    Neoplasma; 1996; 43(6):417-9. PubMed ID: 8996568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
    Lemez P; Maresová J
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
    Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
    Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
    Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
    Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
    Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
    Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
    Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P; Urbánek V
    Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring cardiotoxicity of anthracyclines in children and possibilities of its prevention].
    Sromová T; Strnadová V; Hrstková H
    Vnitr Lek; 2002 Jul; 48(7):649-56. PubMed ID: 12197409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardioxane in pediatric oncohematology].
    Kurmashov VI; Gavrilova IE; Maiakova SA; Popa AV; Morozova OV; Ivanova LF; Kurdiukov BV; Gavrikova NV; Il'iashenko VV; Terzich M
    Vopr Onkol; 1997; 43(4):456-9. PubMed ID: 9381705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
    J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.
    Herman EH; Ferrans VJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):15-21. PubMed ID: 9768819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.